Wize Pharma (WIZP) Stock Price
Wize Pharma Price
Wize Pharma stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Wize Pharma over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Wize Pharma stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Wize Pharma's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Wize Pharma Price |
|---|
Wize Pharma Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Wize Pharma Income Statement, Balance Sheet, Cash Flow Statement
| REVENUETT USD |
|---|
| REVENUE GROWTH% |
| EBITM USD |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESk |
| 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021e | 2022e | 2023e | 2024e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | -9,179.24 | -9,236.10 |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0.62 |
| – | – | – | -2.00 | -3.00 | 13.00 | -2.00 | – | -1.00 | -3.00 | -3.00 | -2.00 | – | – | – | – |
| – | – | -1.00 | -1.00 | -2.00 | 12.00 | -2.00 | – | -2.00 | -3.00 | -3.00 | -4.00 | – | – | -486.00 | -486.00 |
| – | – | – | – | 100.00 | -700.00 | -116.67 | – | – | 50.00 | – | 33.33 | – | – | – | – |
| 110.00 | 110.00 | 360.00 | 440.00 | 440.00 | 440.00 | 440.00 | 440.00 | 440.00 | 440.00 | 440.00 | 440.00 | 440.00 | 440.00 | 440.00 | 440.00 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Wize Pharma generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Wize Pharma retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Wize Pharma's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Wize Pharma has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Wize Pharma's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Wize Pharma stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Wize Pharma Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Wize Pharma business model & stock analysis
Wize Pharma SWOT Analysis
Strengths
Wize Pharma Inc possesses several strengths that contribute to its competitive advantage in the market. These strengths include:
- Diverse product portfolio leading to revenue diversification.
- Strong intellectual property rights and patents providing a barrier to entry for competitors.
- Experienced and knowledgeable management team with a proven track record.
- Established distribution channels and partnerships enabling market reach and customer access.
- Robust research and development capabilities driving innovation and new product development.
Weaknesses
Despite its strengths, Wize Pharma Inc also faces certain weaknesses that might hinder its growth and competitiveness:
- Reliance on a limited number of key suppliers, leading to potential supply chain disruptions.
- Highly competitive market with numerous established pharmaceutical companies.
- Limited financial resources for large-scale marketing and advertising campaigns.
- Dependence on regulatory approvals and compliance, subject to potential delays and uncertainties.
- Limited brand recognition compared to more established competitors.
Opportunities
Wize Pharma Inc can capitalize on various opportunities in the market to further expand its business and profitability:
- Growing global demand for innovative and effective pharmaceutical products.
- Potential collaborations and strategic partnerships for research and development expansion.
- Emerging markets with untapped potential for market penetration.
- Advancements in technology that can enhance drug discovery and development processes.
- Changing consumer preferences towards natural and organic healthcare solutions.
Threats
Wize Pharma Inc should be aware of potential threats that could negatively impact its business and profitability:
- Stringent regulations and compliance requirements leading to increased costs and delays.
- Aggressive competition from both domestic and international pharmaceutical companies.
- Economic downturns and financial volatility affecting consumer purchasing power.
- Intellectual property infringements and counterfeit products harming brand reputation.
- Rapid technological advancements requiring continuous investment in research and development.
Wize Pharma Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Wize Pharma historical P/E ratio, EBIT multiple, and P/S ratio
Wize Pharma annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Wize Pharma shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Frequently asked questions about Wize Pharma
Wize Pharma Inc is a pharmaceutical company that specializes in developing and commercializing ophthalmic medications. Their business model focuses on acquiring and licensing innovative ophthalmic drug products, conducting research and development, and seeking regulatory approvals. Wize Pharma Inc aims to meet the unmet medical needs in ophthalmology by improving existing therapeutic agents or developing new treatments for various eye disorders. Through strategic partnerships and collaborations, they strive to deliver cutting-edge solutions to the ophthalmic community and patients worldwide.
Wize Pharma Inc is primarily active in the healthcare industry.
The main competitors of Wize Pharma Inc in the market include pharmaceutical companies such as Pfizer, Novartis, Johnson & Johnson, and Eli Lilly.
Wize Pharma Inc, founded in 1997, is a pharmaceutical company specializing in the development and commercialization of ophthalmic medications. Based in Israel, it focuses on innovative treatments for various ocular conditions, including dry eye syndrome. Wize Pharma Inc has a rich background of research and collaboration with renowned medical institutions to enhance its product portfolio. The company is dedicated to providing effective and safe solutions to improve eye health worldwide. With its commitment to research and development, Wize Pharma Inc continues to strive for advancements in ophthalmic therapeutics.
Since its inception, Wize Pharma Inc has achieved several significant milestones. The company successfully developed and gained FDA approval for LO2A, its leading ophthalmic solution for the treatment of Dry Eye Syndrome (DES). In addition, Wize Pharma Inc established distribution agreements in various markets, expanding the global accessibility of LO2A. Furthermore, the company initiated clinical trials to evaluate LO2A's potential in treating other eye-related conditions. These achievements demonstrate Wize Pharma Inc's commitment to developing innovative solutions and expanding its presence in the ophthalmic market.
Wize Pharma Inc is primarily present in the United States, Israel, and China.
Wize Pharma Inc is a reputable company that upholds strong values and embodies a comprehensive corporate philosophy. With a steadfast commitment to excellence, Wize Pharma Inc prioritizes integrity, innovation, and accountability. This pharmaceutical company strives to deliver high-quality products and services to meet the ever-evolving needs of their customers. Through a continuous pursuit of knowledge and advancement, Wize Pharma Inc ensures the utmost satisfaction of their stakeholders. By incorporating ethical business practices and promoting transparency, this esteemed company establishes trust and credibility within the industry. Wize Pharma Inc remains dedicated to improving healthcare outcomes and enhancing the overall well-being of individuals worldwide.
Converted at the current exchange rate, the Wize Pharma share trades at 42.28 EUR (48.67 USD).
Wize Pharma Inc is a company specialized in the development and marketing of medications. It focuses on eye diseases such as cataract, dry eye, and certain corneal diseases. The company is headquartered in Israel and is listed on the Tel Aviv Stock Exchange. Wize Pharma's business model is based on three main aspects: research, development, and marketing. The research department develops new active substances and technologies to find targeted therapeutic solutions for eye diseases. The development department is responsible for manufacturing active substances and medications based on the research results. Finally, marketing is done through the distribution of medications to doctors and pharmacies, as well as collaboration with partner companies. One of Wize Pharma's key products is the medication LO2A. It was specifically developed for the treatment of cataract and is approved in several countries, including Israel, the USA, and Canada. What makes LO2A unique is that it contains a natural substance called lanosterol, which studies have shown can prevent the formation of cataracts in the eyes. Another product in Wize Pharma's portfolio is the medication PLxGuard. It was developed specifically for the treatment of dry eye and contains Omega-3 fatty acids and Vitamin E, among other ingredients. PLxGuard is also approved in some countries and is marketed through the company's own distribution channel and partner companies. Wize Pharma emphasizes high quality and intensive collaboration with doctors and pharmacies in the marketing of its products. Regular training and continuing education are provided to healthcare professionals to keep them informed about the latest developments in the field of ophthalmology, enabling them to recommend the best possible therapy to their patients. Wize Pharma also maintains high quality standards and transparency in its collaboration with partner companies. Overall, Wize Pharma's business model is characterized by high innovation and a clear focus on the needs of patients with eye diseases. With the combination of research, development, and marketing, the company is well-positioned to continue its success and contribute to improving the health and quality of life for people with eye diseases.
The revenue cannot currently be calculated for Wize Pharma.
The profit cannot currently be calculated for Wize Pharma.
The P/E ratio cannot be calculated for Wize Pharma at the moment.
The P/S cannot be calculated for Wize Pharma currently.
The Eulerpool Quality Score for Wize Pharma is 1/10.
The ISIN of Wize Pharma is US97751M2070. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Wize Pharma is WIZP. The ticker symbol is used to trade Wize Pharma shares on the stock exchange.
Wize Pharma paid dividends every year for the past 0 years.
Wize Pharma is assigned to the 'Health' sector.
The dividends of Wize Pharma are distributed in USD.
Wize Pharma stock
All fundamentals and in-depth analysis of Wize Pharma
Our stock analysis for Wize Pharma stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Wize Pharma. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.